FDA bolsters black box on antidepressants to warn of suicidality in young adults

Share this article:
The FDA asked antidepressant makers to update the black box warnings on their products to caution against increased risks of suicidality in young adults starting on the meds. The proposed labeling warns of increased risk of suicidality for users age 18-24 in the first two months of treatment, but says that scientific data do not show increased risk in adults over than 24 and that those 65 and older have a decreased risk of suicidality. The language also emphasizes that depression and other serious psychiatric disorders treated by the drugs are themselves the biggest danger to patients. Manufacturers have 30 days to submit revised product labels and medication guides to FDA for review. In 2005, FDA asked manufacturers to add a black box warning of a suicidality risk in children and adolescents on the drugs and initiated a review of 295 individual antidepressant trials involving 77,000 adult patients with major depressive disorder or other psychiatric disorders. The FDA’s move stems from the findings of that review.
Share this article:
You must be a registered member of MMM to post a comment.

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.